At a glance
ClinicalIndex Comparison RecordPhase 3Recruiting· 420 target
Drug / intervention
ZG006 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter, Randomized, Controlled, Open-Label Phase III Study Evaluating the Efficacy and Safety of ZG006 for Injection Compared With Investigator-Selected Chemotherapy in Participants With Relapsed Small Cell Lung Cancer
In Brief
A Phase 3 clinical trial evaluating ZG006 and Topotecan for Small-cell Lung Cancer. Currently recruiting, targeting 420 participants across 1 site.
Detailed Summary
The main objective is to compare ZG006 with Investigator-Selected Chemotherapy on prolonging overall survival (OS).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSmall-cell Lung Cancer
CountriesChina
Collaborators--
Timeline
Phase 3Recruiting
2026202720282029
First PostedSep 2025
Enrollment StartDec 2025
TodayJul 2026
Primary CompletionOct 2028
Study CompletionDec 2028
First PostedSep 24, 2025
Enrollment StartDec 12, 2025
Primary CompletionOct 1, 2028
Study CompletionDec 1, 2028
TodayJul 1, 2026
Enrollment to primary: 2.8 yearsPosted 9 months agoPrimary completion in 2.3 years
Interventions
ZG006drug
ZG006 will be administered as an intravenous (IV) infusion.
Topotecandrug
Topotecan will be administered per local standard of care